In this video, Gordon A. Brown, DO, FACS, explores post hoc analyses from CAPItello-281 evaluating increasing PTEN deficiency thresholds and their relationship to treatment response. Understanding how ...
NCCN now subdivides intermediate-risk NMIBC into three actionable strata, enabling more consistent selection of surveillance, intravesical therapy, and adjuvant intensification pathways. IBCG risk ...
The FDA has approved a label update for nadofaragene firadenovec-vncg (Adstiladrin), introducing an accelerated thawing protocol that may reduce preparation time for intravesical administration of the ...
The PRIMARY2 phase 3 trial found that PSMA PET-CT in men with normal or equivocal MRI results safely halved the number of prostate biopsies, maintained non-inferior detection of clinically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results